VIE News and Press, Viela Bio Inc. From 06/16/20

Viela Bio Wins FDA Approval for Autoimmune Treatment Viela Bio ( VIE ) reported that the FDA has given its nod for Uplizna or inebilizumab-cdon for treating adult patients suffering from neuromyelitis optica spectrum disorder who are anti-AQP4 antibody positive. It is estimated that near...

GAITHERSBURG, Md., June 11, 2020 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE) today announced that the U.S. Food and Drug Administration (FDA) has approved UPLIZNA TM (inebilizumab-cdon) for the treatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD) who are anti-AQ...

The FDA approves Viela Bio's (NASDAQ: VIE ) Uplizna (inebilizumab-cdon) for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults who harbor an antibody called anti-aquaporin-4 (AQP4). More news on: Viela Bio, Inc., Healthcare stocks news, Stocks on the move, Re...

This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsen’s 13F stock portfolio on a quarterly basis. It is based on Viking Global’s regulatory 13F Form filed on 05/13/2020. Please visit our Tracking Ole Andreas Halvorsen...

Viela Bio (NASDAQ: VIE ) has priced its public offering of 3.6M common shares at $47.00/share, for expected gross proceeds of ~$169M. More news on: Viela Bio, Inc., Healthcare stocks news, , Read more ...

GAITHERSBURG, Md., May 27, 2020 (GLOBE NEWSWIRE) -- Viela Bio, Inc. (Nasdaq:VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory diseases, today announced the pricing of an underwritten public offering of 3,600,000 shares of its common st...

Viela Bio (NASDAQ: VIE ) intends to offer and sell 3M common shares in a public offering. More news on: Viela Bio, Inc., Healthcare stocks news, , Read more ...

GAITHERSBURG, Md., May 26, 2020 (GLOBE NEWSWIRE) -- Viela Bio, Inc. (Nasdaq:VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory diseases, today announced that it intends to offer and sell, subject to market and other conditions, 3,0...

Image source: The Motley Fool. Viela Bio Inc   (NASDAQ: VIE) Q1 2020 Earnings Call May 13, 2020 , 5:00 p.m. ET Operator Continue reading

Viela Bio, Inc. (VIE) Q1 2020 Earnings Conference Call May 13, 2020 17:00 ET Company Participants Mitchell Chan - Chief Financial Officer Bing Yao - Chairman & Chief Executive Officer Bill Ragatz - Vice President, Head of Commercial Jorn Drappa - Chief Medical Officer &...